Would you offer neoadjuvant chemoimmunotherapy to a woman with clinical T3 N0 M0 triple negative metaplastic breast cancer?  

Yes, assuming she is fit, I would offer this patient the neoadjuvant KEYNOTE-522 regimen of multi-agent chemo + immunotherapy. To my knowledge, there is no high quality evidence to suggest that metaplastic tumors should be treated differently than standard histology triple-negative tumors (though we...